Avenue Therapeutics logo

Avenue TherapeuticsNASDAQ: ATXI

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

27 June 2017

Next earnings report:

18 March 2025

Last dividends:

N/A

Next dividends:

N/A
$3.84 M
-88%vs. 3y high
10%vs. sector
-vs. 3y high
-vs. sector
-91%vs. 3y high
48%vs. sector
-vs. 3y high
-vs. sector

Price

regular market | Wed, 20 Nov 2024 14:30:00 GMT
$2.01-$0.04(-1.95%)

Dividend

No data over the past 3 years
No data over the past 3 years

Analysts recommendations

Institutional Ownership

ATXI Latest News

Avenue Therapeutics to Participate in Maxim Group's 2024 Healthcare Virtual Summit
globenewswire.com09 October 2024 Sentiment: POSITIVE

MIAMI, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced that Alexandra MacLean, M.D., Chief Executive Officer of Avenue Therapeutics, will participate in a fireside chat at Maxim Group's 2024 Healthcare Virtual Summit on Tuesday, October 15, 2024 at 1:30 PM ET.

Avenue Therapeutics to Participate in Upcoming Investor Conferences
globenewswire.com03 September 2024 Sentiment: POSITIVE

MIAMI, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced that Alexandra MacLean, M.D., Chief Executive Officer of Avenue Therapeutics, will participate in the following upcoming investor conferences:

Avenue Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights
globenewswire.com09 August 2024 Sentiment: POSITIVE

- Last patient visit complete in Phase 1b/2a clinical trial of AJ201 for spinal and bulbar muscular atrophy; topline data anticipated in second half of 2024 –

Why Is Avenue Therapeutics (ATXI) Stock Up 59% Today?
InvestorPlace29 November 2023 Sentiment: POSITIVE

Avenue Therapeutics (NASDAQ: ATXI ) stock is rising higher after the company revealed a major investment from Robert Davidow. According to a filing with the Securities and Exchange Commission (SEC), Davidow now holds a 14.5% stake in the specialty pharmaceutical company.

What type of business is Avenue Therapeutics?

Avenue Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders. The company was incorporated in 2015 and is based in Bay Harbor Islands, Florida. Avenue Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.

What sector is Avenue Therapeutics in?

Avenue Therapeutics is in the Healthcare sector

What industry is Avenue Therapeutics in?

Avenue Therapeutics is in the Biotechnology industry

What country is Avenue Therapeutics from?

Avenue Therapeutics is headquartered in United States

When did Avenue Therapeutics go public?

Avenue Therapeutics initial public offering (IPO) was on 27 June 2017

What is Avenue Therapeutics website?

https://www.avenuetx.com

Is Avenue Therapeutics in the S&P 500?

No, Avenue Therapeutics is not included in the S&P 500 index

Is Avenue Therapeutics in the NASDAQ 100?

No, Avenue Therapeutics is not included in the NASDAQ 100 index

Is Avenue Therapeutics in the Dow Jones?

No, Avenue Therapeutics is not included in the Dow Jones index

When was Avenue Therapeutics the previous earnings report?

No data

When does Avenue Therapeutics earnings report?

The next expected earnings date for Avenue Therapeutics is 18 March 2025